Neil Versel
Journalist at Freelance
Experienced #healthcare & #lifesciences #journalist looking for #writing #editing work. @MSACoalition volunteer. @WUSTL grad. Ironman finisher.
Articles
-
Dec 9, 2024 |
healthcaredive.com | Neil Versel
James Phillips was working as an emergency physician at Beth Israel Deaconess Medical Center in Boston in 2015 when a man walked into Brigham and Women’s Hospital across the street and shot and killed cardiovascular surgeon Michael Davidson. Though Phillips was physically unharmed, the shooting served as a reminder of the several times he had been assaulted on the job. There was one time when a patient spat blood, contaminated with hepatitis C, on him.
-
Jul 29, 2024 |
biospace.com | Neil Versel
Pictured: A red illustration of a businessman walking through a door/iStock, lerbank Welcome to the second in a regular series of rundowns of people coming and going from executive positions at biopharma companies that BioSpace covers. This column will highlight the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits. While there were no blockbuster moves in the last two weeks on the scale of the Feb.
-
Jul 23, 2024 |
biospace.com | Neil Versel
Pictured: Shell game with business executives/Nicole Bean for BioSpace Welcome to the latest update about people coming and going from executive positions at biopharma companies that BioSpace covers, or who have been personally named in lawsuits. Lonza headlines this installment by luring a new CEO from another Swiss CDMO just days after the company made a splash by committing $1.2 billion to buy a massive biologics manufacturing facility in California.
-
Jul 23, 2024 |
biospace.com | Neil Versel
Pictured: Shell game with business executives/Nicole Bean for BioSpace Welcome to the latest update about people coming and going from executive positions at biopharma companies covered by BioSpace or who have been personally named in lawsuits. Bayer continued its leadership shuffle not only at its world headquarters in Germany but at two U.S.–based subsidiaries. Yet most of the executive movement of late has been at smaller companies.
-
Jul 23, 2024 |
biospace.com | Neil Versel
Robert Hariri/Celularity photo Iovance Biotherapeutics priced its recently approved Amtagvi, the first-ever cell therapy of its type, at $515,000. Bristol Myers Squibb’s CAR-T treatment Breyanzi, which received FDA approval for two additional indications in March, carries a list price of about $487,000.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 8K
- Tweets
- 10K
- DMs Open
- No
I lost my dad to an incurable disease in 2012. I subsequently served for 6 years on the board of @MissionMSA. I'll be participating in a 5K walk Oct 5 in Elmwood Park, IL and I encourage you to join me or donate if you are able. Thank you! https://t.co/9D24978Xq5
Just published: a listicle I wrote for @Tech_Networks about #AI and #machinelearning for scientific data handling. #lifesciences #drugdiscovery #genomics #medicalimaging #climatescience https://t.co/5ANMKtnhkJ (registration required to download)
It's almost laundry day so I'm scraping the back of the closet. Today I grabbed an old pair of pants that possibly belonged to my grandpa. Surprisingly, they fit nicely. However, I discovered these business cards in the pocket. PalmOne hasn't existed since 2005. 😱 #digitalhealth https://t.co/exyFrGildg
